Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

Trading in Eli Lilly and Company LLYis quiet on Wednesday. This follows yesterday's drop of almost 6%. The move was driven by a downgrade. But the selloff may be over. A reversal could even occur. The ...

Eli Lilly LLY remains a dominant player in the global obesity market, with much of its recent growth driven by itsblockbuster ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.

Eli Lilly (LLY) stock is lower today, after HSBC downgraded it to "reduce" from "hold," citing an inflated obesity drug market ...

With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even dominant corporations are susceptible to sharp..

Eli Lilly's stock price is based on growth rates that might fall short.

Nevertheless, a high valuation and reduced free cash flow generation indicate elevated growth expectations along with considerable investment in future growth ...

The commercial engine behind this performance is largely driven by tirzepatid. Sold under the brand names Mounjaro and Zepbound, the drug generated $36.51 billion in revenue during 2025, surpassing ...